Phathom Pharmaceuticals PHAT Stock
Phathom Pharmaceuticals Price Chart
Phathom Pharmaceuticals PHAT Financial and Trading Overview
| Phathom Pharmaceuticals stock price | 10.09 USD |
| Previous Close | 9.59 USD |
| Open | 9.6 USD |
| Bid | 6.91 USD x 200 |
| Ask | 11.57 USD x 200 |
| Day's Range | 9.03 - 9.74 USD |
| 52 Week Range | 4.25 - 18.31 USD |
| Volume | 1.57M USD |
| Avg. Volume | 1.21M USD |
| Market Cap | 736.94M USD |
| Beta (5Y Monthly) | 0.567 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.09 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.7 USD |
PHAT Valuation Measures
| Enterprise Value | 1.13B USD |
| Trailing P/E | N/A |
| Forward P/E | 6.4211254 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.5967484 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 5.521 |
| Enterprise Value/EBITDA | -11.779 |
Trading Information
Phathom Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.567 |
| 52-Week Change | 106.68% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 18.31 USD |
| 52 Week Low | 4.25 USD |
| 50-Day Moving Average | 11.73 USD |
| 200-Day Moving Average | 12.84 USD |
PHAT Share Statistics
| Avg. Volume (3 month) | 1.21M USD |
| Avg. Daily Volume (10-Days) | 1.11M USD |
| Shares Outstanding | 79.76M |
| Float | 60.39M |
| Short Ratio | 7.34 |
| % Held by Insiders | 4.73% |
| % Held by Institutions | 88.44% |
| Shares Short | 10.29M |
| Short % of Float | 13.58% |
| Short % of Shares Outstanding | 12.90% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -76.77% |
| Operating Margin (ttm) | -26.54% |
| Gross Margin | 84.93% |
| EBITDA Margin | -46.87% |
Management Effectiveness
| Return on Assets (ttm) | -20.14% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 204.89M USD |
| Revenue Per Share (ttm) | 2.72 USD |
| Quarterly Revenue Growth (yoy) | 104.40% |
| Gross Profit (ttm) | 174.02M USD |
| EBITDA | -96034000 USD |
| Net Income Avi to Common (ttm) | -157300000 USD |
| Diluted EPS (ttm) | -2.09 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 180.9M USD |
| Total Cash Per Share (mrq) | 2.27 USD |
| Total Debt (mrq) | 547.22M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.212 |
| Book Value Per Share (mrq) | -4.242 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -97492000 USD |
| Levered Free Cash Flow (ttm) | -77528624 USD |
Profile of Phathom Pharmaceuticals
| Country | United States |
| State | NJ |
| City | Florham Park |
| Address | 100 Campus Drive |
| ZIP | 07932 |
| Phone | 877 742 8466 |
| Website | https://www.phathompharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 371 |
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Q&A For Phathom Pharmaceuticals Stock
What is a current PHAT stock price?
Phathom Pharmaceuticals PHAT stock price today per share is 10.09 USD.
How to purchase Phathom Pharmaceuticals stock?
You can buy PHAT shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Phathom Pharmaceuticals?
The stock symbol or ticker of Phathom Pharmaceuticals is PHAT.
Which industry does the Phathom Pharmaceuticals company belong to?
The Phathom Pharmaceuticals industry is Biotechnology.
How many shares does Phathom Pharmaceuticals have in circulation?
The max supply of Phathom Pharmaceuticals shares is 79.76M.
What is Phathom Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Phathom Pharmaceuticals PE Ratio is now.
What was Phathom Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Phathom Pharmaceuticals EPS is -2.09 USD over the trailing 12 months.
Which sector does the Phathom Pharmaceuticals company belong to?
The Phathom Pharmaceuticals sector is Healthcare.
Phathom Pharmaceuticals PHAT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}